These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Prediction of left ventricular dysfunction progression in patients with a first ST-elevation myocardial infarction--contribution of cystatin C assessment.
    Author: Derzhko R, Plaksej R, Przewlocka-Kosmala M, Kosmala W.
    Journal: Coron Artery Dis; 2009 Nov; 20(7):453-61. PubMed ID: 19741512.
    Abstract:
    OBJECTIVES: Left ventricular (LV) dysfunction is a major cause of poor outcome after myocardial infarction. We sought to investigate the factors that might contribute to the prediction of postinfarct LV dysfunction progression, and whether the addition of cystatin C (CystC) to this assessment might be useful. METHODS: NT-proBNP, CRP, CystC, and troponin I were measured in 150 patients with a first ST-elevation myocardial infarction (STEMI) who were followed up for 6 months. Echocardiography was performed at discharge and follow-up. RESULTS: In multivariable logistic regression, LV ejection fraction decrease at follow-up exceeding 0.2 was independently predicted by CRP [odds ratio (OR): 1.09, 95% confidence interval (CI): 1.05-1.13, P<0.0001], multivessel disease (OR: 8.83, 95% CI: 4.01-19.41, P<0.001), and left anterior descending artery involvement (OR: 5.09, 95% CI: 1.60-16.22, P<0.006); whereas peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity ratio (E/E') exceeding 15 indicating elevated LV filling pressure by CystC (OR: 3.53, 95% CI: 1.11-11.26, P<0.01), diabetes (OR: 4.04, 95% CI: 1.58-10.58, P<0.005), and multivessel disease (OR: 4.09, 95% CI: 1.52-11.05, P<0.006). CRP, NT-proBNP, and CystC were among the independent determinants of clinical outcomes (heart failure hospitalizations, mortality, and recurrent ischemic events). Receiver operator characteristic analyses identified CRP being the most valuable in discriminating LV ejection fraction decrease exceeding 0.2 and CystC in discriminating E/E' exceeding 15. CONCLUSION: Using multiple biomarkers may contribute to the better prediction of LV dysfunction progression and the risk of adverse cardiac events in patients with STEMI. CystC may improve this evaluation, especially with regard to the development of echocardiographic features of elevated LV filling pressure.
    [Abstract] [Full Text] [Related] [New Search]